Intranasal Peptide Delivery: Mechanism Guide

Intranasal peptide delivery is one of the most actively studied administration routes in preclinical neuropeptide research, because the nasal cavity offers anatomical pathways that other routes do not. This mechanism guide explains how researchers conceptualize nose-to-brain transport and mucosal absorption when investigating peptides such as Semax, Selank, and Dihexa in laboratory models. The focus here is strictly on the biology of the delivery route — the receptors, epithelia, and transport pathways that studies have examined — not on any human application.

Research Use Only Disclaimer: All products and information referenced here are for laboratory research use only. They are not for human or veterinary use, are not intended to diagnose, treat, cure, or prevent any disease, and have not been evaluated by the FDA. Nothing below constitutes medical guidance or a dosing protocol. Handling guidance describes laboratory preparation of research materials only.

Why the Nasal Route Is Studied for Peptides

Peptides are notoriously difficult molecules to deliver. They are large, polar, and susceptible to enzymatic degradation, which limits oral bioavailability and challenges their ability to cross the blood-brain barrier. The nasal cavity has become a focal point of research because a portion of the nasal mucosa is in direct anatomical continuity with the central nervous system — a feature no other peripheral surface shares. This makes intranasal administration a compelling model system for studying how neuroactive peptides might reach the brain compartment while partially bypassing systemic circulation and first-pass metabolism.

Understanding the distinction between the two dominant hypotheses — direct nose-to-brain transport versus systemic mucosal absorption — is central to interpreting the research literature. Most studies suggest both pathways operate simultaneously, with their relative contribution depending on the molecule, the formulation, and the deposition site within the nasal cavity.

The Nasal Cavity: A Map of Relevant Regions

The nasal cavity is not uniform. Research on deposition patterns divides it into functionally distinct regions, each with different absorption characteristics:

The olfactory region occupies only a small fraction (roughly 3–10% in humans) of the total nasal surface and sits high in the cavity, which is why deposition targeting is such a heavily studied variable. The respiratory region, by contrast, is large and richly perfused, making it the main contributor to systemic uptake.

Pathway 1: Direct Nose-to-Brain Transport

The olfactory and trigeminal nerves provide the anatomical basis for direct transport hypotheses. Because these cranial nerves originate in the CNS and terminate in the nasal mucosa, they create a physical route that partially circumvents the blood-brain barrier. Research models have examined several sub-mechanisms:

Olfactory nerve pathway

• Intracellular (transcellular) route: Studies suggest some molecules are taken up by olfactory sensory neurons via endocytosis and transported along axons to the olfactory bulb — a slow process operating over hours.
• Extracellular (paracellular) route: Research indicates a faster pathway in which molecules move through intercellular clefts and perineural spaces surrounding olfactory nerve bundles, reaching the CSF and olfactory bulb within minutes in animal models.

Trigeminal nerve pathway

The trigeminal nerve innervates both the respiratory and olfactory epithelia and enters the brain at the pons. Preclinical tracer studies have examined its role in delivering molecules to caudal brain regions, complementing the more rostral distribution associated with the olfactory route.

For CNS-oriented research peptides, these pathways are why the intranasal format is studied so intensively. Peptides like Semax and Selank — both short peptides with documented central mechanisms — are frequently discussed in the context of nose-to-brain research precisely because their molecular targets reside in the CNS. Larger, more lipophilic constructs such as Dihexa, studied for hepatocyte growth factor/c-Met pathway modulation, present different transport considerations that researchers evaluate case by case.

Pathway 2: Mucosal (Systemic) Absorption

The respiratory mucosa's dense capillary bed and its drainage directly into systemic venous return (bypassing hepatic first-pass metabolism) make it a route for peptide entry into blood. From there, a molecule capable of crossing the blood-brain barrier can reach the CNS by the conventional vascular route. Key variables studied in mucosal absorption research include:

• Molecular weight and lipophilicity — smaller, more lipophilic peptides show higher passive permeability across the epithelium.
• Enzymatic activity — the nasal mucosa contains peptidases and proteases that degrade peptides, a major factor limiting bioavailability.
• Mucociliary clearance — cilia continuously sweep the mucus layer toward the nasopharynx, giving formulations a limited residence window (typically 15–20 minutes) before clearance.
• Tight junctions — paracellular transport is restricted by junctional complexes, a barrier that permeation-enhancer research seeks to modulate.

Formulation Variables Studied to Modulate Delivery

Because both pathways are constrained by clearance and enzymatic barriers, a large body of research examines how formulation influences transport efficiency. Commonly studied variables include:

• Absorption enhancers — surfactants, chitosan, and cyclodextrins studied for transiently loosening tight junctions.
• Enzyme inhibitors — co-formulated agents examined for protecting peptides from mucosal peptidases.
• Mucoadhesive systems — gels and polymer carriers investigated for prolonging residence time against mucociliary clearance.
• Viscosity and droplet size — spray plume characteristics that influence whether deposition reaches the olfactory region versus the anterior cavity.

These variables are exactly why the nasal spray research format exists as a distinct area of study, and why researchers often compare it against reconstituted solutions. For a side-by-side of the two formats, see Nasal Spray vs Reconstituted Peptide Formats.

Laboratory Handling Considerations

For research preparations, peptides are typically supplied as lyophilized powder and reconstituted with bacteriostatic or sterile water for laboratory use. General handling practices documented in the literature include storing lyophilized material at −20°C, keeping reconstituted solutions refrigerated and protected from repeated freeze-thaw cycles, and minimizing light exposure for photosensitive sequences. These are laboratory storage parameters for maintaining compound integrity in an in-vitro research setting — not usage instructions. NeuroLabs peptides are ≥99% purity and third-party COA-tested to support reproducible research.

Format-Specific Research Guides

For deeper coverage of individual compounds studied in intranasal formats, see the dedicated research guides for Semax, Selank, and Dihexa.

Frequently Asked Questions

Below are common questions researchers raise about the mechanisms behind this delivery route.